Media.Player

Amide Inhibitors of Human Secreted Phospholipase A2

Technology Benefits

Potential drugs for the treatment of MS and spinal cord injuries. High degree of specificity respectively for the sPLA2.

Detailed Technology Description

UC San Diego researchers have developed novel amide compounds for the treatment of inflammation. The new molecules are potent inhibitors of secreted PLA2 (sPLA2).

Supplementary Information

Patent Number: US8759392B2
Application Number: US2010994136A
Inventor: Dennis, Edward A. | Kokotos, George | Constantinou-Kokotou, Violetta | David, Samuel
Priority Date: 24 Jul 2008
Priority Number: US8759392B2
Application Date: 20 Jan 2011
Publication Date: 24 Jun 2014
IPC Current: A61K0031225
US Class: 514547 | 554036
Assignee Applicant: The Regents of the University of California
Title: Amides as inhibitors of human secreted phospholipase A2
Usefulness: Amides as inhibitors of human secreted phospholipase A2
Summary: (I) are useful for treating inflammatory conditions.
Novelty: New substituted amide compounds are secreted phospholipase A2 inhibitors useful for treating inflammatory conditions

Industry

Biomedical

Sub Category

Pathogen

Application No.

8759392

Others

State Of Development

This technology is offered exclusively or nonexclusively in the U.S. and/or worldwide territories. A commercial sponsor for potential future research is sought.

Related Materials

Antonopoulou, G., Barbayianni, E., Magrioti, V., Cotton, N., Stephens, D., Constantinou-Kokotou,V., Dennis, E.A. and Kokotos, G., Structure-Activity Relationships of Natural and Non-Natural Amino Acid-Based Amide and 2-Oxoamide Inhibitors of Human Phospholipase A2 Enzymes, Bioorg.Med.Chem., 16, 10257-10269 (2008).

Related Technologies

• Selective Phospholipase A2 Inhibitors of Neurological Diseases

Additional Technologies by these Inventors

• Selective Phospholipase A2 Inhibitors of Neurological Diseases

Tech ID/UC Case

19410/2009-002-0

Related Cases

2009-002-0

*Abstract

Recent studies have revealed an important role for the enzyme phospholipase A2 (PLA2) in various aspects of inflammation in the peripheral and central nervous system. PLA2 consists of a superfamily of enzymes involved in the turnover of phospholipids; their metabolic products can induce both inflammation and demyelination. Therefore, PLA2 enzymes are good candidates as drug targets for the treatment.

*IP Issue Date

Jun 24, 2014

*Principal Investigator

Name: Violetta Constantinou-Kokotou

Department:

Name: Samuel David

Department:

Name: Edward Dennis

Department:

Name: George Kokotos

Department:

Country/Region

USA